Axsome Therapeutics, Inc. (AXSM) Financial Statements (2023 and Earlier)

Company Profile

Business Address 22 CORTLANDT STREET, 16TH FLOOR
NEW YORK, NY 10007
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments86,473183,876219,96613,96934,02136,618
Cash and cash equivalents86,473183,876219,96613,96934,02136,618
Other undisclosed current assets451484131,2461,2781,381
Total current assets:86,518184,025220,37915,21535,30037,999
Noncurrent Assets
Operating lease, right-of-use asset6601,739 
Property, plant and equipment28453315268101
Other noncurrent assets323317140112188113
Total noncurrent assets:1,2672,109170164256214
TOTAL ASSETS:87,785186,134220,55015,37935,55638,213
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,58516,76813,6835,2644,4735,208
Accounts payable13,14913,50410,9433,6873,4354,081
Accrued liabilities  683526333587
Employee-related liabilities4,0502,8702,0561,051705539
Interest and dividends payable385394    
Debt  2,6023,2913,269269
Other undisclosed current liabilities5,4806,6708,2102,2664,4331,694
Total current liabilities:23,06523,43824,49510,82212,1757,171
Noncurrent Liabilities
Long-term debt and lease obligation49,09048,90417,3333,6196,6639,470
Long-term debt, excluding current maturities49,09048,32217,3333,6196,6639,470
Operating lease, liability 582 
Other undisclosed noncurrent liabilities (582)    
Total noncurrent liabilities:49,09048,90417,3333,6196,6639,470
Total liabilities:72,15572,34141,82714,44118,83816,641
Stockholders' equity
Stockholders' equity attributable to parent15,630113,793178,72293816,71721,571
Common stock444332
Additional paid in capital424,826392,585354,614108,48593,30069,211
Accumulated deficit(409,199)(278,796)(175,895)(107,550)(76,585)(47,641)
Total stockholders' equity:15,630113,793178,72293816,71721,571
TOTAL LIABILITIES AND EQUITY:87,785186,134220,55015,37935,55638,213

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(124,707)(99,141)(67,245)(32,847)(27,164)(27,544)
Operating loss:(124,707)(99,141)(67,245)(32,847)(27,164)(27,544)
Nonoperating expense
(Investment Income, Nonoperating)
(5,696)(2,566)(1,240)(1,127)(1,340)(132)
Interest and debt expense (1,717)    
Loss before gain (loss) on sale of properties:(130,403)(103,424)(68,485)(33,974)(28,505)(27,676)
Other undisclosed net income 5231393,008  
Net loss:(130,403)(102,901)(68,345)(30,965)(28,505)(27,676)
Other undisclosed net income (loss) attributable to parent    (439)474
Net loss available to common stockholders, diluted:(130,403)(102,901)(68,345)(30,965)(28,943)(27,202)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(130,403)(102,901)(68,345)(30,965)(28,505)(27,676)
Comprehensive loss, net of tax, attributable to parent:(130,403)(102,901)(68,345)(30,965)(28,505)(27,676)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: